EUPRAXIA PHARMACEUTICALS INC.
EPRX
Analytical Summary
EUPRAXIA PHARMACEUTICALS INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.
4-Year Financial Trajectory
AnnualBullish Indicators
- No bullish signals detected.
Bearish Risks
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 40-F ↗ | FY 2024 Dec 31, 2024 40-F ↗ | FY 2023 Dec 31, 2023 40-F ↗ | FY 2022 Dec 31, 2022 40-F ↗ |
|---|---|---|---|---|
| EPS Growth YoY (%) |
-35.5%
Weak
↓
Weak
Declining
Year-over-year change in earnings per share
Optimal:
> 10%
|
35.0%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
-21.9%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
— |
| Net Income Growth YoY (%) |
-51.3%
Weak
↓
Weak
Declining
Year-over-year change in net income |
9.6%
Fair
Fair
Year-over-year change in net income |
-52.6%
Weak
Weak
Year-over-year change in net income |
— |
| FCF Growth YoY (%) |
19.2%
Good
↑
Good
Improving
Year-over-year change in free cash flow |
-3.2%
Weak
Weak
Year-over-year change in free cash flow |
-14.8%
Weak
Weak
Year-over-year change in free cash flow |
— |
| Metric | FY 2025 Dec 31, 2025 40-F ↗ | FY 2024 Dec 31, 2024 40-F ↗ | FY 2023 Dec 31, 2023 40-F ↗ | FY 2022 Dec 31, 2022 40-F ↗ |
|---|---|---|---|---|
| Effective Tax Rate (%) (%) |
-0.0%
Excellent
↓
Excellent
Declining
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
-0.0%
Excellent
↑
Excellent
Improving
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
-0.1%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
| FCF / Net Income (x) |
0.74x
Caution
↓
Caution
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
1.18x
Fair
↑
Fair
Improving
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.73x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.78x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
| Metric | FY 2025 Dec 31, 2025 40-F ↗ | FY 2024 Dec 31, 2024 40-F ↗ | FY 2023 Dec 31, 2023 40-F ↗ | FY 2022 Dec 31, 2022 40-F ↗ |
|---|---|---|---|---|
| Return on Common Equity (%) (%) |
-47.0%
Weak
↑
Weak
Improving
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-413%)
|
-76.3%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-609%)
|
— |
-237.5%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-1683%)
|
| Metric | FY 2025 Dec 31, 2025 40-F ↗ | FY 2024 Dec 31, 2024 40-F ↗ | FY 2023 Dec 31, 2023 40-F ↗ | FY 2022 Dec 31, 2022 40-F ↗ |
|---|---|---|---|---|
| Sales/Revenue/Turnover (USD) | $0.00 | $0.00 | $0.00 | — |
| Depreciation Expense (USD) | $237.72K | $171.72K | $155.53K | $147.89K |
| Net Income, GAAP (USD) | $-38.58M | $-25.50M | $-28.22M | $-18.49M |
| Operating Cash Flow (USD) | $-28.55M | $-29.99M | $-20.68M | $-14.40M |
Secondary lens
Benchmark Lens
Compare EPRX against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare EPRX against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for EPRX
No bullish signals detected
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How EPRX compares to all companies
Peer Comparison
EPRX vs similar peers
Compare EPRX with peers
Stack EPRX against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 4 years · 4 quarters